Physician profile
Majorie Lee
NPI 1861422958
$12,017.96
in general payments reported to CMS, 2019-2025
26 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,814 · 2020: $850 · 2021: $709 · 2022: $1,861 · 2023: $1,709 · 2024: $2,127 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,724 · Education: $59.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,724.09 |
| Education | $59.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,068.47 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,255.93 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $927.51 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $810.33 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.03 | 2019-2024 | Ofev |
| Genentech USA, INC. | $521.74 | 2019-2022 | |
| Optinose US, INC. | $361.38 | 2019-2024 | |
| Amgen INC. | $358.35 | 2022-2024 | Tezspire |
| Mallinckrodt Enterprises LLC | $292.15 | 2019 | |
| Insmed, INC. | $290.92 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $276.99 | 2019-2020 | |
| Mylan Specialty L.P. | $253.03 | 2020-2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $226.80 | 2022-2023 | Quviviq |
| Viiv Healthcare Company | $123.07 | 2025 | Apretude |
| Exact Sciences Corporation | $122.43 | 2025 | The Cologuard Plus Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $119.39 | 2020 | |
| Electromed, INC. | $104.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $76.51 | 2019 | |
| Gilead Sciences, INC. | $60.24 | 2022 | |
| Philips North America LLC | $51.60 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $43.99 | 2022 | |
| Currax Pharmaceuticals LLC | $28.73 | 2022 | |
| Abbvie INC. | $24.55 | 2023 | |
| United Therapeutics Corporation | $18.08 | 2021 | |
| Merck Sharp & Dohme LLC | $15.07 | 2019 | |
| Circassia INC. | $12.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majorie Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.